Results 101 to 110 of about 20,787 (190)

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

A comparative evaluation of bioequivalence of Gan & Lee glargine U300 and Toujeo® in Chinese healthy male participants

Frontiers in Endocrinology
BackgroundTo assess the bioequivalence between Gan & Lee (GL) glargine U300 and Toujeo® regarding pharmacokinetics (PK), pharmacodynamics (PD), and safety in Chinese healthy male participants.MethodsA single-center, randomized, double-blind, single ...
Xiaoli Li, Anshun He, Bingyan Liu, Rongfang Shan, Juan Zhu, Xiaoyue Li, Tian Xie, Yue Li, Mengmeng Chen, He Su, Chaoyang Zhang, Lufeng Li, Dongmei Cheng, Juan Chen, Ying Wang, Yue Su, Yuanyuan Xu, Zhuoran Li, Huan Zhou, Wei Chen, Yuanyuan Liu   +20 more
doaj   +1 more source

Associations of modifiable preconception, pregnancy and postpartum factors with health outcomes for women with type 2 diabetes and their children: A systematic review and meta‐analysis of observational studies

Diabetic Medicine, Volume 43, Issue 2, February 2026.
Abstract Aim Type 2 diabetes (T2D) in pregnancy is increasingly common and associated with suboptimal outcomes for these women and their children. We aimed to synthesize observational evidence on associations of modifiable preconception, pregnancy and postpartum risk factors with perinatal outcomes among women with pregestational T2D.
Danielle Schoenaker, Eleanor Dyer, Nicola Heslehurst, Grainne Kent, Sowmiya Gunabalasingam, Lily Hopkins, Artemis Kyrka, Rivka Lebrett, Angela C. Flynn, Sara L. White, Claire L. Meek, Rita Forde   +11 more
wiley   +1 more source

Insulin glargine

Journal of Institute of Medicine Nepal, 2008
Abstract: Insulin glargine is a long-acting human insulin analog prepared using recombinant DNA technology. It is the first long-acting analog of human insulin to be approved for clinical use. It is administered once daily and has a smooth 24 hour time-action profile that provides effective glycemic control with minimal risk of hypoglycemia.
D.K. Upadhayay, S. Palaian, M. Prabhu, P.R. Shankar, P. Mishra   +4 more
openaire   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Targeting acute hyperglycaemia in clinical practice [PDF]

, 2007
The UKPDS established the benefit of tight glycaemic control in preventing microvascular disease but was unable to demonstrate an effect on cardiovascular disease.
Heller, S.
core   +1 more source

Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1350-1358, February 2026.
Abstract Aims To evaluate treatment‐emergent antidrug antibodies (TE ADA) in once‐weekly basal insulin efsitora‐treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety.
Yun Wang, Sihe Wang, Wei Wang, Xiaoqi Li, Jennifer Leohr, Vitoria Pires, Michelle L. Katz, Christopher J. Child, Robert J. Konrad   +8 more
wiley   +1 more source

Effect of a homemade diet compared to a commercial diet on glycaemic variability and glycaemic control assessed by continuous glucose monitoring system in diabetic dogs: a randomised crossover study

Journal of Small Animal Practice, Volume 67, Issue 2, Page 172-180, February 2026.
Objectives To evaluate the effects of a homemade diet and a commercial diet on glycaemic control and glycaemic variability of diabetic dogs monitored with the FreeStyle Libre continuous glucose monitoring system. Materials and Methods Prospective randomised crossover study including ten client‐owned diabetic dogs on insulin treatment with good ...
A. M. Tardo, C. G. Vecchiato, E. Gherlinzoni, A. Corsini, S. Corradini, F. Del Baldo, G. Biagi, F. Fracassi   +7 more
wiley   +1 more source

Insulin glargine use and breast cancer: a systematic review and meta-analysis

Electronic Physician, 2019
Background: Insulin is widely used in the treatment of diabetes. There is an increasing concern regarding the association between insulin glargine use and breast cancer.
Ibrahim Altedlawi Albalawi, Hyder Osman Mirghani   +1 more
doaj   +1 more source

Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

Frontiers in Endocrinology
BackgroundUltra-long-acting insulin analogs [insulin degludec (IDeg) and insulin glargine 300 units/mL (IGla-300)] offer a longer duration of action with less risk of hypoglycemia compared to other long-acting insulins.
Eman N. Alhmoud, Mohamed Omar Saad, Nabil Elhadi Omar, Nabil Elhadi Omar   +3 more
doaj   +1 more source